Skip to main content
. 2021 Jan 18;11:615980. doi: 10.3389/fimmu.2020.615980

Figure 4.

Figure 4

Distal intestinal antigen processing and presentation-related genes expression of juvenile hybrid grouper (Epinephelus fuscoguttatus♀×E. lanceolatus♂) fed the experimental diets for 8 weeks. Results are represented as mean ± SE (n = 4). (A) PI3K RS5, phosphatidylinositol 3-kinase regulatory subunit 5; 3-PDK1, 3-phosphoinositide dependent kinase-1; TSC1, tuberous 1; TSC2, tuberous 2; Akt, serine/threonine-protein kinase; IKKα, inhibitor of nuclear factor kappa-B kinase subunit α; (B) Rheb, Ras homolog enriched in brain; Raptor, regulatory associated protein of mTOR; PRAS40, proline-rich Akt1 substrate 1; mTOR, mammalian target of rapamycin; mTOR C1, mammalian target of rapamycin complex 1; mTOR C2, mammalian target of rapamycin complex 2; (C) deptor, DEP domain-containing mTOR-interacting protein; mLST8, target of rapamycin complex subunit lst8; TEL2, telomere length regulation protein; 4EBP1, eukaryotic translation initiation factor 4E binding protein 1; 4EBP2, eukaryotic translation initiation factor 4E binding protein 2; p70 S6K, ribosomal protein S6 kinase β1; (D) EIF4E, translation initiation factor 4E; EIF4B, translation initiation factor 4B; S6, small subunit ribosomal protein S6; Sin1, target of rapamycin complex 2 subunit; RICTOR, rapamycin-insensitive companion of mTOR; PRR5, proline-rich protein 5; (E) RhoA, Ras homolog gene family, member A; PKCα, protein kinase C α; SGK1, serum/glucocorticoid-regulated kinase 1; CIITA, major histocompatibility complex class II trans-activator; RFX5, regulatory factor X5; CREB1, cyclic AMP-responsive element-binding protein 1; NFY, nuclear transcription factor Y subunit α; (F) MHC I, major histocompatibility complex class I antigen; MHC II, major histocompatibility complex class II antigen; GILT, gamma-interferon-inducible-lysosomal thiol reductase; AEP, asparaginyl endopeptidase; CTSB, cathepsin B; TCR, T cell receptor; CD4, T-cell surface glycoprotein. Significance was evaluated by one-way ANOVA followed by Tukey’s multiple range tests. FM, control diet; GL, containing 2% 11S diet, GH, containing 8% 11S diet, GH-SB, containing 8% 11S and 0.13% SB diet. a,b,cMean values among all treatments with different letters were significantly different when the interaction was significant (P < 0.05).